Spot-Scanning Hadron Arc (SHArc) Therapy: A Study With Light and Heavy Ions.
Journal
Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247
Informations de publication
Date de publication:
Historique:
received:
02
09
2020
revised:
29
12
2020
accepted:
18
01
2021
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
epublish
Résumé
To evaluate the clinical potential of spot-scanning hadron arc (SHArc) therapy with a heavy-ion gantry. A series of in silico studies was conducted via treatment plan optimization in FRoG and the RayStation TPS to compare SHArc therapy against reference plans using conventional techniques with single, parallel-opposed, and 3-field configurations for 3 clinical particle beams (protons [p], helium [ SHArc plans exhibited similar target coverage with unique treatment attributes and distributions compared with conventional planning, with carbon ions demonstrating the greatest potential for tumor control and normal tissue sparing among the arc techniques. All SHArc plans exhibited a low-dose bath outside the target volume with a reduced maximum dose in normal tissues compared with single, parallel-opposed, and 3-field configuration plans. Moreover, favorable LET SHArc therapy offers potential treatment benefits such as increased normal tissue sparing. Without explicit consideration of oxygen concentration during treatment planning and optimization, SHArc-C may mitigate tumor hypoxia-induced loss of efficacy. Findings justify further development of robust SHArc treatment planning toward potential clinical translation.
Identifiants
pubmed: 33817410
doi: 10.1016/j.adro.2021.100661
pii: S2452-1094(21)00019-1
pmc: PMC8010580
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100661Informations de copyright
© 2021 The Author(s).
Références
Med Phys. 2020 Jun;47(6):2450-2460
pubmed: 32141079
Phys Med Biol. 2017 May 7;62(9):3814-3827
pubmed: 28252446
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):427-434
pubmed: 28068248
Sci Rep. 2015 Nov 24;5:17016
pubmed: 26596243
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):541-51
pubmed: 17869667
Radiat Res. 2006 Oct;166(4):629-38
pubmed: 17007551
Curr Mol Med. 2009 May;9(4):442-58
pubmed: 19519402
Sci Rep. 2020 Feb 21;10(1):3199
pubmed: 32081928
Radiat Res. 2000 Nov;154(5):485-96
pubmed: 11025645
Br J Cancer. 2000 Aug;83(3):354-9
pubmed: 10917551
Semin Nucl Med. 2020 Nov;50(6):562-583
pubmed: 33059825
Cancers (Basel). 2018 Oct 23;10(11):
pubmed: 30360576
Br J Radiol. 2020 Mar 1;93(1107):20190469
pubmed: 31860338
Radiother Oncol. 2004 Dec;73 Suppl 2:S186-90
pubmed: 15971340
Phys Med. 2020 Aug;76:166-172
pubmed: 32683269
Med Phys. 2006 Sep;33(9):3105-15
pubmed: 17022202
Br J Radiol. 2011 Jun;84(1002):485-98
pubmed: 21606068
Phys Med Biol. 2010 Nov 21;55(22):6721-37
pubmed: 21030747
Med Phys. 2020 Oct;47(10):5274-5286
pubmed: 32737870
Phys Med Biol. 2016 Nov 7;61(21):7586-7599
pubmed: 27716637
Phys Med Biol. 2016 Nov 7;61(21):N565-N574
pubmed: 27740944
Phys Med Biol. 2020 Aug 31;65(16):165002
pubmed: 32413889
Int J Radiat Biol. 2013 Oct;89(10):782-93
pubmed: 23627742
Adv Drug Deliv Rev. 2017 Jan 15;109:26-44
pubmed: 27919760
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922791
Radiat Res. 2011 Nov;176(5):587-602
pubmed: 21823972
J Radiat Res. 2016 Aug;57 Suppl 1:i90-i98
pubmed: 26983987
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):188-94
pubmed: 23920395
Nat Rev Clin Oncol. 2013 Jul;10(7):411-24
pubmed: 23689752
Med Phys. 2020 Jun;47(5):2072-2084
pubmed: 32040214
Phys Med Biol. 2017 Jun 21;62(12):5180-5197
pubmed: 28333688
Phys Med Biol. 2019 Feb 08;64(4):045008
pubmed: 30641490
Phys Med Biol. 2020 Feb 12;65(4):045005
pubmed: 31968318
Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):891-7
pubmed: 9240659
Phys Med Biol. 2013 Jun 7;58(11):3871-95
pubmed: 23681217
Phys Med. 2019 Aug;64:123-131
pubmed: 31515011
Sci Rep. 2018 Oct 4;8(1):14829
pubmed: 30287930
Phys Med. 2021 Jan;81:273-284
pubmed: 33353795
Acta Oncol. 2018 Mar;57(3):435-437
pubmed: 28774218
Radiother Oncol. 2019 Aug;137:130-136
pubmed: 31100606
Acta Oncol. 2015;54(9):1614-22
pubmed: 26198655
Acta Oncol. 2019 Oct;58(10):1463-1469
pubmed: 31241377
Nature. 1956 Nov 3;178(4540):978-9
pubmed: 13378491
Int J Mol Sci. 2019 Nov 30;20(23):
pubmed: 31801300
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Phys Med Biol. 2020 Aug 19;65(16):165006
pubmed: 32428896
Med Phys. 2011 Dec;38(12):6347-50
pubmed: 22149817
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2185-90
pubmed: 16609033
Phys Med Biol. 2017 Jun 7;62(11):N244-N256
pubmed: 28384125
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1107-1116
pubmed: 27869083
Acta Oncol. 2014 Jan;53(1):25-32
pubmed: 24020629
Phys Med Biol. 2011 Jun 7;56(11):3251-68
pubmed: 21540489
Int J Radiat Oncol Biol Phys. 2020 Nov 1;108(3):779-791
pubmed: 32504659
Acta Oncol. 2010 Oct;49(7):1170-6
pubmed: 20831510
Phys Med Biol. 2020 Apr 24;65(9):095007
pubmed: 32028273
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):194-205
pubmed: 31610250
Acta Oncol. 2020 Oct;59(10):1178-1185
pubmed: 32421375